Preclinical Characterization of Antioxidant Quinolyl Nitrone QN23 as a New Candidate for the Treatment of Ischemic Stroke

Nitrones are encouraging drug candidates for the treatment of oxidative stress-driven diseases such as acute ischemic stroke (AIS). In a previous study, we found a promising quinolylnitrone, QN23, which exerted a neuroprotective effect in neuronal cell cultures subjected to oxygen–glucose deprivation and in experimental models of cerebral ischemia. In this paper, we update the biological and pharmacological characterization of QN23. We describe the suitability of intravenous administration of QN23 to induce neuroprotection in transitory four-vessel occlusion (4VO) and middle cerebral artery occlusion (tMCAO) experimental models of brain ischemia by assessing neuronal death, apoptosis induction, and infarct area, as well as neurofunctional outcomes. QN23 significantly decreased the neuronal death and apoptosis induced by the ischemic episode in a dose-dependent manner and showed a therapeutic effect when administered up to 3 h after post-ischemic reperfusion onset, effects that remained 11 weeks after the ischemic episode. In addition, QN23 significantly reduced infarct volume, thus recovering the motor function in a tMCAO model. Remarkably, we assessed the antioxidant activity of QN23 in vivo using dihydroethidium as a molecular probe for radical species. Finally, we describe QN23 pharmacokinetic parameters. All these results pointing to QN23 as an interesting and promising preclinical candidate for the treatment of AIS.

[1]  J. Montaner,et al.  Characterization of a CholesteroNitrone (ISQ-201), a Novel Drug Candidate for the Treatment of Ischemic Stroke , 2020, Antioxidants.

[2]  Correction to: Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. , 2019, Stroke.

[3]  R. Sacco,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. , 2019, Stroke.

[4]  D. Hadjipavlou-Litina,et al.  Novel Quinolylnitrones Combining Neuroprotective and Antioxidant Properties. , 2019, ACS chemical neuroscience.

[5]  J. Montaner,et al.  New Quinolylnitrones for Stroke Therapy: Antioxidant and Neuroprotective ( Z)- N- tert-Butyl-1-(2-chloro-6-methoxyquinolin-3-yl)methanimine Oxide as a New Lead-Compound for Ischemic Stroke Treatment. , 2019, Journal of medicinal chemistry.

[6]  Á. Chamorro,et al.  Emergent Uric Acid Treatment is Synergistic with Mechanical Recanalization in Improving Stroke Outcomes in Male and Female Rats , 2018, Neuroscience.

[7]  M. Hill,et al.  Long-term neurological, vascular, and mortality outcomes after stroke , 2018, International journal of stroke : official journal of the International Stroke Society.

[8]  J. Montaner,et al.  Quinolinyl Nitrone RP19 Induces Neuroprotection after Transient Brain Ischemia. , 2017, ACS chemical neuroscience.

[9]  Chun-Qiang Lu,et al.  Edaravone-Encapsulated Agonistic Micelles Rescue Ischemic Brain Tissue by Tuning Blood-Brain Barrier Permeability , 2017, Theranostics.

[10]  M. I. Ayuso,et al.  Stress Granule Induction after Brain Ischemia Is Independent of Eukaryotic Translation Initiation Factor (eIF) 2α Phosphorylation and Is Correlated with a Decrease in eIF4B and eIF4E Proteins* , 2016, The Journal of Biological Chemistry.

[11]  J. Montaner,et al.  CholesteroNitrones for Stroke. , 2015, Journal of medicinal chemistry.

[12]  H. Feys,et al.  Functional and Motor Outcome 5 Years After Stroke Is Equivalent to Outcome at 2 Months: Follow-Up of the Collaborative Evaluation of Rehabilitation in Stroke Across Europe , 2015, Stroke.

[13]  Y. Hara.  Brain plasticity and rehabilitation in stroke patients. , 2015, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[14]  B. Basavarajappa,et al.  CB1 receptor‐mediated signaling underlies the hippocampal synaptic, learning, and memory deficits following treatment with JWH‐081, a new component of spice/K2 preparations , 2014, Hippocampus.

[15]  R. Rodrigo,et al.  Oxidative stress and pathophysiology of ischemic stroke: novel therapeutic opportunities. , 2013, CNS & neurological disorders drug targets.

[16]  P. Sengupta.  The Laboratory Rat: Relating Its Age With Human's , 2013, International journal of preventive medicine.

[17]  M. I. Ayuso,et al.  The Translational Repressor eIF4E-Binding Protein 2 (4E-BP2) Correlates with Selective Delayed Neuronal Death after Ischemia , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  John H. Zhang,et al.  RIGOR Guidelines: Escalating STAIR and STEPS for Effective Translational Research , 2012, Translational Stroke Research.

[19]  D. Hadjipavlou-Litina,et al.  Α-aryl-N-alkyl nitrones, as potential agents for stroke treatment: synthesis, theoretical calculations, antioxidant, anti-inflammatory, neuroprotective, and brain-blood barrier permeability properties. , 2012, Journal of medicinal chemistry.

[20]  J. Neilson,et al.  Regulation of Synaptic Structure and Function by FMRP-Associated MicroRNAs miR-125b and miR-132 , 2010, Neuron.

[21]  P. Bath,et al.  Effects of NXY‐059 in experimental stroke: an individual animal meta‐analysis , 2009, British journal of pharmacology.

[22]  P. Deyn,et al.  The complexity of neurobiological processes in acute ischemic stroke , 2009, Clinical Neurology and Neurosurgery.

[23]  Chul-Hee Choi,et al.  Nitrones as therapeutics. , 2008, Free radical biology & medicine.

[24]  A. Alcázar,et al.  Regulatory proteins of eukaryotic initiation factor 2‐alpha subunit (eIF2α) phosphatase, under ischemic reperfusion and tolerance , 2007, Journal of neurochemistry.

[25]  P. Proctor,et al.  SAINT-I worked, but the neuroprotectant is not NXY-059. , 2007, Stroke.

[26]  M. Castelló-Ruiz,et al.  Dietary phytoestrogens improve stroke outcome after transient focal cerebral ischemia in rats , 2006, The European journal of neuroscience.

[27]  W. Hacke,et al.  Tolerability of NXY-059 at Higher Target Concentrations in Patients With Acute Stroke , 2003, Stroke.

[28]  M. Dehouck,et al.  In vitro blood–brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions , 2002, Brain Research.

[29]  K. Lees,et al.  Tolerability and Pharmacokinetics of the Nitrone NXY-059 in Patients With Acute Stroke , 2001, Stroke.

[30]  R. Neumar,et al.  Brain ischemia and reperfusion: molecular mechanisms of neuronal injury , 2000, Journal of the Neurological Sciences.

[31]  L. Pitts,et al.  Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. , 1986, Stroke.

[32]  M. Iwamura,et al.  Novel Formation of Nitroxide Radicals by Radical Addition to Nitrones , 1967 .

[33]  John H. Zhang,et al.  Neuroprotective Therapy for Stroke and Ischemic Disease , 2017 .

[34]  A. Bach.  Targeting Oxidative Stress in Stroke , 2017 .

[35]  C. Edenius,et al.  Pharmacokinetics of NXY-059, a nitrone-based free radical trapping agent, in healthy young and elderly subjects. , 2002, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[36]  P. Weinstein,et al.  Reversible middle cerebral artery occlusion without craniectomy in rats. , 1989, Stroke.

[37]  G. Consales,et al.  Phenyl-T-butyl-nitrone is active against traumatic shock in rats. , 1986, Free radical research communications.

[38]  D. Harrison,et al.  Aha Scientific Statement on Behalf of the American Heart Association Council on Basic Cardiovascular Sciences. Measurement of Reactive Oxygen Species, Reactive Nitrogen Species, and Redox-dependent Signaling in the Cardiovascular System: a Scientific Statement from the American Heart Association. Me , 2022 .